4 results
To determine the pharmacokinetic properties of a new elacridar formulation
The primary objective of this study is to obtain clinical proof of principle that the addition of a PgP/BCRP inhibitor increases CNS concentrations of tyrosine kinase inhibitors by inhibition of drug efflux transporter function in the blood brain…
The primary objective involves the safety of in vivo Raman/scattering during endoscopy. Therefore, we will assess safety parameters (AEs, SAEs, SUSARs). Secondary objective involves the feasibility of the probe-based scattering/(stimulated) Raman…
In this study, we want to learn more about the effect and safety of Ceralasertib plus Durvalumab on the inhibition of tumour growth, and also to better understand NSCLC and associated health problems.We compare the effect and safety of Ceralasertib…